Inactive Instrument

Highlights Stellar Biotechnologies Inc Nasdaq

Equities

CA85855A3029

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS	24/06	CI
Edesa Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	11/05	CI
Edesa Biotech, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	10/02	CI
Edesa Biotech, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	16/12	CI
Edesa Biotech, Inc. Reports Final Phase 2b Results for Dermatitis Study	21/11	CI
Edesa Biotech, Inc. Approves Updated Phase 3 Trial Design for Edesa Biotech?S ARDS Drug	25/23/25	CI
Edesa Biotech, Inc. to Receive Up to CAD 23 Million in Funding from Federal Government	12/23/12	CI
Edesa Biotech to Implement 1-for-7 Reverse Share Split; Stock Declines	10/23/10	MT
Edesa Biotech, Inc. Publishes Phase 2 Substudy Results of ARDS Drug Candidate	28/23/28	CI
Edesa Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	10/23/10	CI
Edesa Biotech's Ards Drug Inhibits Inflammation from Influenza and Other Pathogens	28/23/28	CI
Edesa Biotech Appoints Biotech Deal Veteran to CFO, Effective July 15, 2023	27/23/27	CI
Edesa Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	12/23/12	CI
Edesa Biotech, Inc. to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting	17/23/17	CI
Edesa Biotech and FDA Agree on Primary Endpoint for Phase 3 ARDS Drug Study	15/23/15	CI
Edesa Biotech, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	10/23/10	CI
Edesa Biotech Receives Regulatory Approval for Phase 2 Vitiligo Study	01/23/01	CI
Edesa Biotech, Inc. Reports Topline Phase 2B Results for Dermatology Drug	17/23/17	CI
Edesa Biotech Secures Fast-Track Designation for Potential Acute Respiratory Distress Syndrome Drug Candidate	20/22/20	MT
Fda Grants Fast Track to Edesa Biotech's Ards Drug Candidate	20/22/20	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Stellar Biotechnologies Inc Nasdaq

Equities

CA85855A3029

Highlights

Filters